Replies to post #748851 on NorthWest Biotherapeutics Inc (NWBO)

[skitahoe]

Thanks Lykiri,

I've got to believe that Dr. Mulholland would know about Poly-ICLC, it would be surprising if he can't get that as well.

People with the funds will try most anything, if successful it will be difficult to know whether everything was needed. Sometimes the decision to try the unorthodox therapies first can be harmful, many believe that Steve Jobs could have lived longer if he'd not experimented so much before turning to approved therapies.

Gary

[ATLnsider]

Thanks Lykiri, it’s also very impressive that NWBio / Advent was able to make 22 DCVax-L vaccine doses for this patient (Charles Nap) from his resected tumor.

That means, based on the prescribed dosing regimen for DCVax-L (6 shots the first year, and then 2 shots each year thereafter), they were able to make DCVax-L dosages to cover 9 full years of treatment:



https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-018-1507-6

That would be 6 shots the first year, with 16 doses remaining (22 - 6 = 16 ). Then the 16 shots remaining, at 2 maintenance DCVax—L shots per year thereafter would last an additional 8 years, for a total of 9 years of DCVax-L vaccine treatments.

That makes it laughable when detractors say stupid things like “DCVax-L is too expensive or cost too much at $250,000 (about £200,000) and will not be appraised by NICE to be covered by the NHS national insurance in the U.K.

When you take $250,000 for the total cost of 9 years of DCVax-L treatment, then the treatment cost would be about $27,778 per year ($250,000 / 9 years), of $11,363 per dose ($250,000 / 22).

The truth is, DCVax-L is very cheap compared to other cell therapies and gene therapies. Even though, all solid tumor cancer patients will not have enough tumor resected to produce 9 or 10 years of doses, even at 3 years or 5 years of doses, the cost of DCVax-L is very affordable.